Research programme: recombinant antibody therapeutics - Affimed/ProBioGenAlternative Names: Tandabs- AffImed/ProBioGen; Tetravalent antibodies- Affimed/ProBioGen
Latest Information Update: 22 Jul 2010
At a glance
- Originator Affimed Therapeutics
- Developer ProBioGen
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Feb 2006 Preclinical trials in Cancer in Germany (unspecified route)